期刊文献+

复方新诺明预防性治疗对降低艾滋病抗病毒治疗患者机会性感染的经济学效益评价 被引量:4

原文传递
导出
摘要 目的了解复方新诺明预防性治疗对降低艾滋病抗病毒治疗患者机会性感染或不良反应的效果。方法采用回顾性调查的方法,选取108例服用(干预组)与84例未服用(对照组)复方新诺明的艾滋病病例,对其在接受艾滋病抗病毒治疗一年中的机会性感染或不良反应发生情况和治疗费用进行经济学效益评价。结果两组间年内门诊机会性感染或不良反应就诊频次差异有统计学意义(t=4.11,P<0.05);两组间门诊治疗费用(t=4.17,P<0.05)和住院费用(t=14.48,P<0.05)差异有统计学意义。结论艾滋病抗病毒治疗患者服用复方新诺明不但可以有效降低机会性感染或不良反应的发生率,并且减少抗机会性感染药物治疗费用。
出处 《中国公共卫生管理》 2013年第6期771-773,共3页 Chinese Journal of Public Health Management
  • 相关文献

参考文献5

二级参考文献26

  • 1王爱霞.重视肺孢子菌肺炎的诊断和治疗[J].传染病信息,2005,18(2):51-52. 被引量:12
  • 2郜桂菊,张福杰,姚均,赵红心,卢联合,李鑫.HIV感染者/AIDS患者CD_4^+细胞计数与机会性感染对应关系的临床分析[J].中国艾滋病性病,2005,11(4):241-243. 被引量:87
  • 3王焕玲,李太生,王爱霞,盛瑞媛,范洪伟,刘正印,滑立伟,秦树林,邓国华.艾滋病合并肺孢子菌肺炎22例临床分析[J].中华内科杂志,2005,44(9):652-655. 被引量:34
  • 4郑煜煌,陈军,雷建华,赖力英,朱映华,何艳,罗虹雨,周华英,丁佩佩,张春迎,李慧.高效抗逆转录病毒疗法治疗HIV—1感染者的免疫学变化[J].中华皮肤科杂志,2006,39(5):281-284. 被引量:22
  • 5王爱霞,王福生,王清玥,王健,冯铁建,卢洪洲,孙洪清,孙永涛,叶寒辉,李太生,李兴旺,刘正印,邢玉兰,何云,汪宁,吴昊,吴南屏,张福杰,周曾全,宫恩聪,赵红心,赵敏,唐小平,徐莲芝,徐小元,曹韵贞,康来仪,蒋岩,蔡卫平,樊庆泊,潘孝彰.艾滋病诊疗指南[J].中华传染病杂志,2006,24(2):133-144. 被引量:631
  • 6Bartlett JG, Gallant JE. Medical management of HIV infection[M]. Maryland: Johns Hopkins Medicine Health Publishing Business Group, 2007:390.
  • 7U. S. Public Health Service(USPHS) and Infectious Disease Society of America( IDSA). 2001 USPHA/IDSA guidelines for the prevention of opportunistic infected with human immunodeficiency virus [ J ].MMWR,2001,1 - 68.
  • 8Burman W, El-Sadr WE, Matts J, et al. Continued low rates of Mycobacterium avium complex and bacterial pneumonia despite withdrawal of azithromycin prophylaxis among patients with CD4^+ cell rebound[A]. Program and abstracts of the 9th Conference on Retroviruses and Opportunictic Infections [ C]. Seattle, Washington, February 24 -28,2002,631.
  • 9Yangco BG, Von Bargen JC, Moorman AC, et al. Can PCP prophylaxis be safely discontinued among clinically improving HIV patients[ C] ?[ Abstract I - 262 ]. 38th ICAAC, San Diego, CA, 1998.
  • 10Anglaret X, Chene G, Attia A, et al Early chemotherapy with trimethoprin-sulphamethoxazole for HIV-1 infected adults in Abidjan,Cote d' Ivoire: a randomised control trial[J ]. Lancet, 1999,353:1463-1468.

共引文献169

同被引文献85

  • 1吴尊友.全球及中国艾滋病流行现况与发展趋势[J].中华疾病控制杂志,1997,9(4):333-338. 被引量:4
  • 2汪宁.中国艾滋病流行现状与防治对策[J].社会福利(实务版),2005(10):29-31. 被引量:15
  • 3艾滋病诊疗指南[J].中国感染与化疗杂志,2006,6(4):265-279. 被引量:42
  • 4中国疾病预防控制中心性病艾滋病预防控制中心.国家免费艾滋病抗病毒药物治疗手册[M].3版.北京:人民卫生出版社,2012.
  • 5Kumarasamy N, Venkatesh KK, Devaleenol B, et al. Factors associated with mortality among HIV-infected patients in the era of highly active antiretroviral therapy in southern India[J]. Int J Infect Dis,2010,14(2): 127-131.
  • 6Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America[J]. MMWR Recomm Rep, 2009, 58(RR-4): 1-207.
  • 7Mermin J, Lule J, Ekwaru JP et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda[J].Lancet,2004, 364(9443): 1428-1434.
  • 8Kelly M N, Shellito J E. Current understanding of pneumoeysfis immunology[J].Future Microbiol,2010,5(1): 43-65.
  • 9Younng T, Oliphant CE, Araoyinbo I, et al. Co-trimoxazole prophylaxis in HIV: the evidence[J].S Afr Med J,2008, 98(4): 258-259.
  • 10Lim PL, Zhou J, Ditangco RA,et al. Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database[J] .J Int AIDS Soc,2012,15(1 ): 1.

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部